What is the extent of COVID-19 vaccine hesitancy in Bangladesh? : A cross-sectional rapid national survey

Author:

Ali MohammadORCID,Hossain AhmedORCID

Abstract

AbstractobjectivesTo assess COVID-19 vaccine hesitancy in Bangladesh and identify population subgroups with higher odds of vaccine hesitancy.designA nationally representative cross-sectional survey was used. Univariate analysis was employed to compute vaccine hesitancy proportions and compare them across groups and multiple logistic regression analyses were performed to compute the adjusted odds ratio.settingBangladeshparticipantsA total of 1134 participants from the general population, aged 18 years and above.outcome measuresPrevalence and predictors of vaccine hesitancy.results32.5% of participants showed COVID-19 vaccine hesitancy. Hesitancy was high among respondents who were males, over age 60, unemployed, from low-income families, from central Bangladesh including Dhaka, living in rented houses, tobacco users, politically affiliated, participants who did not believe in the vaccine’s effectiveness for Bangladeshis and those who did not have any physical illnesses in the last year. In the multilevel logistic regression models, respondents who were transgender (AOR= 3.62), married (AOR=1.49), tobacco users (AOR=1.33), those who did not get any physical illnesses in the last year (AOR=1.49), those with political affiliations with opposition parties (AOR= 1.48), those who believed COVID-19 vaccines will not be effective for Bangladeshis (AOR= 3.20), and those who were slightly concerned (AOR = 2.87) or not concerned at all (AOR = 7.45) about themselves or a family member getting infected with COVID-19 in the next one year were significantly associated with vaccine hesitancy (p < 0.05).conclusionsGiven the high prevalence of COVID-19 vaccine hesitancy, it is important to promote evidence-based communication, mass media campaigns, and policy initiatives across Bangladesh to reduce vaccine hesitancy among the Bangladeshi population.Strengths and Limitations of the studyThis study is the first its kind to measure COVID-19 vaccine hesitancy in Bangladesh.In this study, randomly selected participants were interviewed face to face, enabling a nearly true representative sample of the Bangladeshi general population.This study identified a wide range of sub-groups of the general population with higher odds of COVID-19 vaccine hesitancy relating to their sociodemographic characteristics in Bangladesh; thus, providing baseline evidence for the low and middle-income and low-resourced countries worldwide.Traditional media and social media influence on COVID-19 vaccine hesitancy was not measured which is a major limitation of this study.

Publisher

Cold Spring Harbor Laboratory

Reference37 articles.

1. World Health Organization. Weekly Operational Update on COVID-19. World Heal Organ [Internet]. 2021;(February):1–10. Available from: https://www.who.int/publications/m/item/weekly-update-on-covid-1916-october-2020

2. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine;N Engl J Med [Internet],2020

3. Baden LR , El Sahly HM , Essink B , Kotloff K , Frey S , Novak R , et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med [Internet]. 2020 Dec 30 [cited 2021 Jan 29];NEJMoa2035389. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2035389

4. Logunov DY , Dolzhikova I V , Shcheblyakov D V , Tukhvatulin AI , Zubkova O V , Dzharullaeva AS , et al. Articles Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet [Internet]. 2021 [cited 2021 Feb 2];0(0). Available from: https://doi.org/10.1016/S0140-6736

5. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK;Lancet [Internet],2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3